DMG-PEG

DMG-PEG is a lipid synthesized via myristoyl glyceride diester pegylation, with oral efficacy. DMG-PEG renders lPEI/DNA nanoparticles hydrophilic and electrically neutral, thereby enhancing their diffusivity and transport capacity in the gastrointestinal mucus layer. DMG-PEG is used to prepare liposomes for siRNA delivery, which can improve transfection efficiency. DMG-PEG maintains high-level glucagon-like peptide-1 (GLP-1) expression in the liver, lung and intestine of type 2 diabetic mouse models, and keeps blood glucose levels within the normal range. DMG-PEG can be used to prepare lipid nanoparticles for mRNA drugs^[1]. In Vitro:DPPC/DMG-PEG/(lPEI/DNA) nanoparticles prepared with DMG-PEG (N/P ratio of 6-16 for 293T cells, N/P ratio of 14 for A549/HeLa cells; 24 h) show increased transfection efficiency in 293T cells with elevated N/P ratios. At an N/P ratio of 14 or higher, they reach a peak transfection efficiency of approximately 76% eGFP-positive cells in 293T cells, and exhibit high transfection efficiency in A549 and HeLa cells at an N/P ratio of 14^[1]. In Vivo:DMG-PEG-coated DPPC/DMG-PEG/(lPEI/DNA) (NP-1-3) (150 μg DNA per mouse; p.o.; single administration) mediates significantly higher levels of transgene (luciferase and GLP-1) expression in the liver, lung and small intestine of normal Balb/c mice, and the expression persists for at least 24 h^[1].
DMG-PEG coated DPPC/DMG-PEG/(lPEI/DNA) (NP-1-3) (150 μg GLP-1 plasmid DNA per mouse; p.o.; once every other day; 3 times in total over 6 days) effectively reduces and maintains blood glucose levels within the normal range in type 2 diabetic db/db mice, while also increasing plasma GLP-1 and insulin levels, improving liver and kidney functions, and causing no acute toxicity^[1].